PIII (P3 Health Partners) YoY EBITDA Growth: 525.91% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PIII P3 Health Partners Inc PIII
47 GF Score
Price $9.35
GF Value $10.70
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is P3 Health Partners YoY EBITDA Growth?

P3 Health Partners PIII +1.85% 47 YoY EBITDA Growth is 525.91% as of Jun. 2026. GuruFocus rates PIII with a GF Score™ of 47/100 and a GF Value™ of $10.70 (Modestly Undervalued). The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. P3 Health Partners's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 525.91%.

P3 Health Partners's EBITDA per Share for the three months ended in Jun. 2026 was $13.63.

P3 Health Partners YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for P3 Health Partners's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

P3 Health Partners YoY EBITDA Growth Chart

P3 Health Partners Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 100.00 0.00 99.22 -388.84 17.29

P3 Health Partners Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,233.33 64.48 -34.30 186.40 525.91
PIII
47GF Score
P3 Health Partners Inc PIII
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

P3 Health Partners YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

P3 Health Partners's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-55.633--67.265)/ | -67.265 |
=17.29 %

P3 Health Partners's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(13.629--3.2)/ | -3.2 |
=525.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 525.91% mean?
P3 Health Partners (PIII) has a YoY EBITDA Growth of 525.91% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for P3 Health Partners and its competitors.
Is P3 Health Partners' YoY EBITDA Growth too high?
P3 Health Partners' current YoY EBITDA Growth is 525.91%. Overall, P3 Health Partners has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does P3 Health Partners' YoY EBITDA Growth compare to DCGO and CCEL?
P3 Health Partners' YoY EBITDA Growth of 525.91% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for P3 Health Partners and its competitors. P3 Health Partners's current YoY EBITDA Growth is 525.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is P3 Health Partners stock overvalued right now?
Based on GuruFocus' analysis, P3 Health Partners (PIII) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.70, compared to a current price of $9.35 — trading 12.6% below its estimated fair value. The current YoY EBITDA Growth is 525.91%. P3 Health Partners' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For P3 Health Partners (PIII), the current YoY EBITDA Growth is 525.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is P3 Health Partners (PIII) Overvalued in 2026?

Based on GuruFocus' analysis, P3 Health Partners stock appears to be undervalued. The current stock price of $9.35 is trading 12.6% below its estimated GF Value™ of $10.70. GuruFocus considers P3 Health Partners to be Modestly Undervalued.

Key valuation signals for PIII:

  • YoY EBITDA Growth: 525.91%
  • GF Value™: $10.70 vs. price of $9.35 (12.6% below fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the PIII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

P3 Health Partners Business Description

Address 2370 Corporate Circle, Suite 300, Henderson, NV, USA, 89074
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
47GF Score

Get the complete analysis for PIII

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.35
Price
$10.70
GF Value